Acumen Pharmaceuticals Stock Price To Earnings To Growth
| ABOS Stock | USD 1.19 0.05 4.03% |
Acumen Pharmaceuticals fundamentals help investors to digest information that contributes to Acumen Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Acumen Stock. The fundamental analysis module provides a way to measure Acumen Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acumen Pharmaceuticals stock.
Acumen | Price To Earnings To Growth |
Acumen Pharmaceuticals Company Price To Earnings To Growth Analysis
Acumen Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.
Current Acumen Pharmaceuticals Price To Earnings To Growth | (0.23) X |
Most of Acumen Pharmaceuticals' fundamental indicators, such as Price To Earnings To Growth, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acumen Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Acumen Price To Earnings To Growth Driver Correlations
Understanding the fundamental principles of building solid financial models for Acumen Pharmaceuticals is extremely important. It helps to project a fair market value of Acumen Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Acumen Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Acumen Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Acumen Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.
| Competition |
Acumen Price Earnings To Growth Ratio
Price Earnings To Growth Ratio |
|
Based on the latest financial disclosure, Acumen Pharmaceuticals has a Price To Earnings To Growth of -0.23 times. This is 132.39% lower than that of the Biotechnology sector and 107.32% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 104.7% higher than that of the company.
Acumen Price To Earnings To Growth Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acumen Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acumen Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Acumen Pharmaceuticals by comparing valuation metrics of similar companies.Acumen Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.
Acumen Fundamentals
| Return On Equity | -0.33 | ||||
| Return On Asset | -0.21 | ||||
| Current Valuation | (100.38 M) | ||||
| Shares Outstanding | 60.08 M | ||||
| Shares Owned By Insiders | 11.23 % | ||||
| Shares Owned By Institutions | 76.56 % | ||||
| Number Of Shares Shorted | 1.74 M | ||||
| Price To Book | 0.33 X | ||||
| Price To Sales | 538.78 X | ||||
| Gross Profit | (43.56 M) | ||||
| EBITDA | (51.61 M) | ||||
| Net Income | (52.37 M) | ||||
| Cash And Equivalents | 189.91 M | ||||
| Cash Per Share | 4.69 X | ||||
| Total Debt | 28.49 M | ||||
| Current Ratio | 37.21 X | ||||
| Book Value Per Share | 3.62 X | ||||
| Cash Flow From Operations | (43.06 M) | ||||
| Short Ratio | 8.97 X | ||||
| Earnings Per Share | (1.38) X | ||||
| Price To Earnings To Growth | (0.23) X | ||||
| Target Price | 10.8 | ||||
| Number Of Employees | 51 | ||||
| Beta | 0.024 | ||||
| Market Capitalization | 71.49 M | ||||
| Total Asset | 310.12 M | ||||
| Retained Earnings | (222.8 M) | ||||
| Working Capital | 233.64 M | ||||
| Net Asset | 310.12 M |
About Acumen Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acumen Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acumen Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acumen Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acumen Stock Analysis
When running Acumen Pharmaceuticals' price analysis, check to measure Acumen Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acumen Pharmaceuticals is operating at the current time. Most of Acumen Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Acumen Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acumen Pharmaceuticals' price. Additionally, you may evaluate how the addition of Acumen Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.